Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 17, Issue 2, 2014, Pages 343-354

  Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Meta analysis; mianserin; mirtazapine; NaSSAs; schizophrenia

Indexed keywords

MIANSERIN; MIRTAZAPINE; PLACEBO;

ADVERSE DRUG REACTION; DISEASE EXACERBATION; DROWSINESS; DRUG TOLERABILITY; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 84891751312     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000667     Document Type: Review

References (49)

1. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S (2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 116:101-106.
2. Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3:247-251.
3. Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784-788.
4. Andreasen NC (1985) Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 11:380-389.
5. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
6. Berk M, Ichim C, Brook S (2001) Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16:87-92.
7. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S (2009) Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 24:233-238.
8. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research T (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71-93.
9. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH, Lee SH (2011) Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 35:208-211.
10. Cohn LD, Becker BJ (2003) How meta-analysis increases statistical power. Psychol Methods 8:243-253.
11. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773.
12. Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17:97-107.
13. Croom KF, Perry CM, Plosker GL (2009) Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS drugs 23:427-452.
14. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
15. Foussias G, Remington G (2010) Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 36:359-369.
16. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64:1115-1122.
17. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (2010) Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35:1053-1062.
18. Guy W, Bonato RR (1970) Manual for the ECDEU assessment battery, 2nd edn. Chevy Chase, MD, National Institute of Mental Health.
19. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
20. Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T, Furutani M, Fujikawa T, Horiguchi J, Yamawaki S (1997) Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 12:199-205.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560.
22. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J (2009) Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 108:245-251.
23. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A III, Assuncao-Talbott S (2009) Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:627-643.
24. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Tran QV, Pikalov A III, Assuncao-Talbott S (2010) Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post-hoc analysis of pooled data from short-and long-term aripiprazole trials. J Psychopharmacol 24:1019-1029.
25. Kay SR, Opler LA, Lindenmayer JP (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl.)7:59-67.
26. Kishi T, Moriwaki M, Kawashima K, Okochi T, Fukuo Y, Kitajima T, Furukawa O, Naitoh H, Fujita K, Iwata N (2010) Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. Neurosci Res 66:340-344.
27. Kishi T, Matsuda Y, Nakamura H, Iwata N (2012) Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 47:149-154.
28. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a) Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
29. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009b) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
30. Liebman JM, Lovell RA, Braunwalder A, Stone G, Bernard P, Barbaz B, Welch J, Kim HS, Wasley JW, Robson RD (1983) CGS 7525A, a new, centrally active alpha 2 adrenoceptor antagonist. Life Sci 32:355-363.
31. Lopez-Munoz F, Rubio G (2011) Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia. Evid Based Ment Health 14:96.
32. Milev P, Ho BC, Arndt S, Andreasen NC (2005) Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 162:495-506.
33. Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J (2006) Vitamin B6 vs. mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 29:68-72.
34. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.
35. Moteshafi H, Stip E (2012) Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf 11:713-732.
36. Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K (1986) Pharmacological properties of MO-8282, a novel antidepressant. Nihon yakurigaku zasshi Folia pharmacologica Japonica 88:309-320.
37. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
38. Pinder RM, van Delft AM (1983) Pharmacological aspects of mianserin. Acta Psychiatr Scand Suppl 302:59-71.
39. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A (1999) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 174:238-242.
40. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A (2003a) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 23:305-308.
41. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R (2003b) Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 13:123-128.
42. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38:167-177.
43. Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, Weizman A (2002) Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol 17:59-64.
44. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:11-19.
45. Singh SP, Singh V, Kar N, Chan K (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 197:174-179.
46. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G (2010) Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int Clin Psychopharmacol 13:433-441.
47. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (2011) Mirtazapine vs. other antidepressive agents for depression. Cochrane Database Syst Rev:CD006528.
48. Yamada K, Furukawa T (1991) Behavioral effects of a new antidepressant, setiptiline. Nihon yakurigaku zasshi Folia pharmacologica Japonica 97:31-39.
49. Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, Di Rosa AE, Meduri M (2004) The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 19:71-76.